title: AKT kinase pathway: a leading target in cancer research.
abstract: AKT1, a serine/threonine-protein kinase also known as AKT kinase, is involved in the regulation of various signalling downstream pathways including metabolism, cell proliferation, survival, growth, and angiogenesis. The AKT kinases pathway stands among the most important components of cell proliferation mechanism. Several approaches have been implemented to design an efficient drug molecule to target AKT kinases, although the promising results have not been confirmed. In this paper we have documented the detailed molecular insight of AKT kinase protein and proposed a probable doxorubicin based approach in inhibiting miR-21 based cancer cell proliferation. Moreover, the inhibition of miR-21 activation by raising the FOXO3A concentration seems promising in reducing miR-21 mediated cancer activation in cell. Furthermore, the use of next generation sequencing and computational drug design approaches will greatly assist in designing a potent drug molecule against the associated cancer cases.
authors: Bioinformatics Division, School of Bio Sciences and Technology, Vellore Institute of Technology University, Vellore, Tamil Nadu 632014, India.
authors: Ambuj
authors: A
authors: Kumar
authors: Vidya
authors: V
authors: Rajendran
authors: Rao
authors: R
authors: Sethumadhavan
authors: Rituraj
authors: R
authors: Purohit
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D019295:Computational Biology; D004317:Doxorubicin / Q000494:pharmacology; D015195:Drug Design; D015507:Drugs, Investigational / Q000494:pharmacology*; D000071316:Forkhead Box Protein O3; D051858:Forkhead Transcription Factors / Q000502:physiology; D020868:Gene Silencing; D006801:Humans; D035683:MicroRNAs / Q000502:physiology; D056004:Molecular Dynamics Simulation; D058990:Molecular Targeted Therapy; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000502:physiology; D009369:Neoplasms / Q000188:drug therapy / Q000201:enzymology; D051059:PTEN Phosphohydrolase / Q000096:biosynthesis / Q000235:genetics / Q000502:physiology; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D051057:Proto-Oncogene Proteins c-akt / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000502:physiology; D012334:RNA, Neoplasm / Q000502:physiology; D015398:Signal Transduction / Q000187:drug effects* / Q000502:physiology
chemical_list: D000970:Antineoplastic Agents; D015507:Drugs, Investigational; C499517:FOXO3 protein, human; D000071316:Forkhead Box Protein O3; D051858:Forkhead Transcription Factors; C524940:MIRN21 microRNA, human; D035683:MicroRNAs; D009363:Neoplasm Proteins; D047428:Protein Kinase Inhibitors; D012334:RNA, Neoplasm; D004317:Doxorubicin; C494918:AKT1 protein, human; D051057:Proto-Oncogene Proteins c-akt; D051059:PTEN Phosphohydrolase; C494929:PTEN protein, human